Terms: = Gastric cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
32 results:
1. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
2. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
3. Diagnosis and treatment of ERBB2-Positive Metastatic Colorectal cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract] [Full Text] [Related]
4. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Lee MX; Wong ALA; Ow S; Sundar R; Tan DSP; Soo RA; Chee CE; Lim JSJ; Yong WP; Lim SE; Goh BC; Wang L; Lee SC
Target Oncol; 2022 Mar; 17(2):141-151. PubMed ID: 35195837
[TBL] [Abstract] [Full Text] [Related]
5. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
6. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
7. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract] [Full Text] [Related]
8. Clonal Architectures Predict Clinical Outcome in gastric Adenocarcinoma Based on Genomic Variation, Tumor Evolution, and Heterogeneity.
Ren C; Wu C; Wang N; Lian C; Yang C
Cell Transplant; 2021; 30():963689721989606. PubMed ID: 33900127
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA-936/erbb4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion.
Liu S; Gong Y; Xu XD; Shen H; Gao S; Bao HD; Guo SB; Yu XF; Gong J
Kaohsiung J Med Sci; 2021 Feb; 37(2):111-120. PubMed ID: 33021020
[TBL] [Abstract] [Full Text] [Related]
10. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
Cotes Sanchís A; Gallego J; Hernandez R; Arrazubi V; Custodio A; Cano JM; Aguado G; Macias I; Lopez C; López F; Visa L; Garrido M; Martínez Lago N; Fernández Montes A; Limón ML; Azkárate A; Pimentel P; Reguera P; Ramchandani A; Cacho JD; Martín Carnicero A; Granja M; Martín Richard M; Hernández Pérez C; Hurtado A; Serra O; Buxo E; Vidal Tocino R; Jimenez-Fonseca P; Carmona-Bayonas A
PLoS One; 2020; 15(7):e0235848. PubMed ID: 32735623
[TBL] [Abstract] [Full Text] [Related]
11. HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of gastric cancer to Trastuzumab.
Bie L; Luo S; Li D; Wei Y; Mu Y; Chen X; Wang S; Guo P; Lu X
Curr Cancer Drug Targets; 2020; 20(9):700-709. PubMed ID: 32364078
[TBL] [Abstract] [Full Text] [Related]
12. The role of erbb4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract] [Full Text] [Related]
13. erbb4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway.
Xu J; Gong L; Qian Z; Song G; Liu J
Oncol Rep; 2018 Jun; 39(6):2892-2898. PubMed ID: 29620274
[TBL] [Abstract] [Full Text] [Related]
14. The her4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.
Shi J; Li F; Yao X; Mou T; Xu Z; Han Z; Chen S; Li W; Yu J; Qi X; Liu H; Li G
Oncogene; 2018 May; 37(22):3022-3038. PubMed ID: 29535422
[TBL] [Abstract] [Full Text] [Related]
15. Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Kim TM; Lee KW; Oh DY; Lee JS; Im SA; Kim DW; Han SW; Kim YJ; Kim TY; Kim JH; Han H; Kim WH; Bang YJ
Cancer Res Treat; 2018 Jul; 50(3):835-842. PubMed ID: 28859471
[TBL] [Abstract] [Full Text] [Related]
16. 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/her4 up-regulation.
Shi X; Zheng C; Li C; Hou K; Wang X; Yang Z; Liu C; Liu Y; Che X; Qu X
Cell Biol Int; 2018 Jan; 42(1):53-62. PubMed ID: 28851073
[TBL] [Abstract] [Full Text] [Related]
17. miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting erbb4 expression.
Song G; Zhang H; Chen C; Gong L; Chen B; Zhao S; Shi J; Xu J; Ye Z
Oncotarget; 2017 Jul; 8(28):45725-45735. PubMed ID: 28501849
[TBL] [Abstract] [Full Text] [Related]
18. Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: A preliminary study.
Liu H; Li F; Zhu Y; Li T; Huang H; Lin T; Hu Y; Qi X; Yu J; Li G
Oncotarget; 2016 Jul; 7(28):43894-43906. PubMed ID: 27270314
[TBL] [Abstract] [Full Text] [Related]
19. HER Family Protein Expression in a Greek Population with gastric cancer. A Retrospective Hellenic Cooperative Oncology Group Study.
Makatsoris T; Tsamandas AC; Strimpakos A; Alexopoulou Z; Dionysopoulos D; Pervana S; Konstantara A; Papakostas P; Samantas E; Rallis G; Dimou A; Pentheroudakis G; Papaparaskeva K; Psyrri A; Kalogeras KT; Syrigos K; Scopa CD; Fountzilas G
Anticancer Res; 2016 Apr; 36(4):1581-90. PubMed ID: 27069134
[TBL] [Abstract] [Full Text] [Related]
20. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract] [Full Text] [Related]
[Next]
